

1 **TITLE:** Capability of the inter-eye differences in osmolarity, break-up time and corneal staining
2 on the diagnostic of dry eye

3

4 **Running Heah:** Inter-eye differences diagnostic of dry eye

5

6 **AUTHORS:**

7 Hugo Pena-Verdeal, OD, MSc, PhD^{1,2} – ORCID: 0000-0001-5103-1374

8 Jacobo Garcia-Queiruga, OD, MSc^{1*} – ORCID: 0000-0001-7216-4512

9 Belen Sabucedo-Villamarin, OD, MSc¹ – ORCID: 0000-0001-5032-620X

10 Maria Jesus Giraldez, OD, MSc, PhD^{1,2} – ORCID: 0000-0001-9595-7486

11 Carlos García-Resúa, OD, MSc, PhD^{1,2} – ORCID: 0000-0002-6804-4478

12 Eva Yebra-Pimentel, OD, PhD^{1,2} – ORCID: 0000-0002-4012-4636

13

14 ¹*Departamento de Física Aplicada (Área de Optometría), Facultade de Óptica e Optometría,*
15 *Universidade de Santiago de Compostela, Santiago de Compostela, Spain*

16 ²*Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.*

17 *Corresponding author: Jacobo Garcia-Queiruga. Facultad de Óptica y Optometría, Campus Vida
18 s/n, Universidad de Santiago de Compostela, 15782 Santiago de Compostela, A Coruña, Galicia,
19 Spain. Tel.: +34 881813610; e-mail: jacobogarcia.queiruga@usc.es

20

21

22

23

24

25

26

27

28

29 **ABSTRACT**

30 **Purpose:** Inter-eye variability is a recognized characteristic of Dry Eye Disease (DED) and has
31 been proposed as a diagnostic indicator in clinical practice. This study aimed to assess the
32 diagnostic potential of the absolute difference between eyes in three key diagnostic tests
33 recommended by the Tear Film and Ocular Surface Society Dry Eye Workshop II (TFOS DEWS
34 II) Diagnostic Methodology report: tear film osmolarity, Fluorescein Break-Up Time (FBUT),
35 and ocular surface staining.

36 **Methods:** A total of 180 participants were included in a cross-sectional study. Before a dry eye
37 examination, participants completed an online self-administered OSDI questionnaire. The TFOS
38 DEWS II diagnostic criteria for DED assessment were used: along with OSDI, osmolarity, FBUT
39 and ocular surface staining were measured in all participants in both eyes following standardized
40 methodology. Based on signs and symptoms, participants were diagnosed as having No DED or
41 DED. After diagnosis, parameters were computed as the right and left eyes' absolute inter-eye
42 difference ($|OD-OS|$).

43 **Results:** Receiver Operating Characteristics analyses for computed parameters were used based
44 on the previous diagnosis. ROC analyses showed that Osmolarity $|OD-OS|$ have a diagnostic
45 capability to differentiate between No DED and DED participants with a cut-off value of 9.5
46 mOsm/L ($AUC = 0.745 \pm 0.052$, $p < 0.003$), whereas FBUT $|OD-OS|$ and Corneal Staining $|OD-$
47 OS $|$ have not (AUC , both $p \geq 0.160$).

48 **Conclusion:** The present study found that the Osmolarity $|OD-OS|$ parameter could be used as a
49 diagnostic indicator for DED assessment, while the FBUT $|OD-OS|$ and the Corneal Staining $|OD-$
50 OS $|$ parameters do not have this capability.

51

52 **Keywords:** Dry Eye Syndromes; Tear Film Osmolarity; Fluorescein Break-Up Time; Ocular
53 Surface Staining; ROC Curve

54

55

56

57 **1. INTRODUCTION**

58 Dry Eye Disease (DED) had been redefined by the Tear Film and Ocular Surface Society in the
59 second Dry Eye Workshop (TFOS DEWS II) as a chronic multifactorial disease of the ocular
60 surface characterized by a loss of homeostasis of the tear film accompanied by ocular symptoms,
61 in which tear film instability and hyperosmolarity, ocular surface inflammation, damage, and
62 neurosensory abnormalities play etiological roles.¹⁻³ The DED may reach to 50% of the population
63 of some areas, impairing the quality of life of those suffering from it.⁴ The inclusion of
64 'homeostasis' in the actual definition implies that DED may be not caused by any single factor but
65 rather by an imbalance of several different systems working in concert.

66 Tear film parameters show little variation, either over time or between eyes in healthy patients,
67 while as the body loses control during an ocular surface disease, the tear film homeostasis loss is
68 reflected as increasing in time or eye-to-eye value changes of the diagnostic test.³ Repeated
69 measurements over a while in several parameters such as osmolarity has been reported as low and
70 stable in healthy participants, nonetheless, DED patients showed an increase and unstable
71 readings in short periods.⁵⁻⁷ Indeed, the variation and increase in diagnostic tests values
72 (heteroscedasticity) is a statistical characteristic of DED indicators because of the
73 physiopathological processes that are implied in the disease, which could be considered a clinical
74 indication of the inherent tear film homeostasis loss.⁸ Furthermore, inter-eye variability may serve
75 as a distinctive characteristic of DED, wherein elevated variations in the metrics across eyes could
76 be leveraged in clinical settings; notably, lower disparities might indicate temporary effects within
77 compensatory mechanisms.^{9,10}

78 The present study aimed to explore the diagnostic capability of the absolute inter-eye differences
79 of the three main diagnostic criteria tests proposed by the TFOS DEWS II Diagnostic
80 Methodology report: tear film osmolarity, tear film Fluorescein Break-Up Time (FBUT) and
81 fluorescein ocular surface staining.

82

83 **2. MATERIALS AND METHODS**

84 **2.1. Sample**

85 A total of 180 participants (mean \pm standard deviations [SDs] = 49.4 \pm 14.1 years) who attended
86 the Optometry Clinic were included in the study. All of them were participants who came to the
87 centre for an ocular surface examination referred by their medical doctor, or the health service of
88 the institution based on dry eye complaints. No participant was using any kind of medication or
89 artificial tears at the time of the study. Participants were excluded if they had a prior history of
90 ocular surgery (including refractive surgery or eyelid tattooing), ocular infections, Meibomian
91 Gland Dysfunction (MGD), blepharitis, glaucoma or general autoimmune or systemic diseases
92 (previous diagnosis of diabetes mellitus, sarcoidosis, Sjögren's syndrome, Lupus, Crohn's
93 disease, Graves' disease, Hashimoto's thyroiditis, Psoriasis, tumours or Multiple sclerosis or
94 active influenza, COVID-19 or pneumonia), were pregnant or breast-feeding or wore contact
95 lenses.^{11,12} All the participants gave their written informed consent to be included in the study and
96 all procedures followed were in accordance with the Helsinki Declaration. The study protocol
97 was approved by the Bioethics Committee of the institution.

98 Before the study, the sample size was calculated based on TFOS DEWS II Diagnostic
99 Methodology report recommended diagnostic tests.¹ For the sample size calculation, the software
100 PS Power and Sample Size Calculations Version 3.1.2 (Copyright© by William D. Dupont and
101 Walton D. Plummer) was used.¹³ The SD reported in the literature on the symptomatology status
102 (Ocular Surface Disease Index [OSDI] score), tear film osmolarity, tear film FBUT, and
103 fluorescein corneal staining was assumed to be 6.7, 4.8 mOsm/L, 2.9 s, and 2 respectively.^{1,14-17}
104 To have 80% power for a significance level of $\alpha = 0.05$ (Type I error associated) to detect a clinical
105 difference between no DED and DED participants of 7.3, 5 mOsm/l, 5 s and 1 respectively, the
106 minimum number of subjects required in each group was 60, 54, 36 and 51 respectively to have
107 a relative ratio control/experimental of 1:1. The highest of those values was used as the reference
108 to the sample size (60 participants) to accomplish a more reliable study. A higher sample was
109 recruited to find a greater impact on the results.

110

111 ***2.2. Study Design and Diagnostic Criteria***

112 A battery of clinical procedures was conducted on both eyes of all participants according to the
113 TFOS DEWS II Diagnostic Methodology report.¹ The first eye to be measured was randomly
114 selected. Tests were always performed in the same order, from the least to the most invasive ¹:
115 tear film osmolarity, tear film FBUT and fluorescein corneal staining. The diagnostic tests cut-
116 off values for the DED diagnosis are stated on Table 1.¹ Participants were classified as DED if a
117 positive symptomology result (OSDI score ≥ 13) combined with a positive result on at least one
118 clinical test in diagnosing dry eye was accomplished in either of the eyes, while were diagnosed
119 as No DED if no one of the inclusion criteria falls out of the cut-off criteria in any of the
120 participant's eyes.¹

121 All these measurements were performed and recorded by the same examiner who was unaware
122 of the results of the questionnaire, in a single session, to avoid interexaminer or intersession
123 variability.^{18,19} During all protocols, the instruments and material used were kept in the same
124 humidity- and temperature-controlled room (temperature 20-23°C, humidity 50-60%).⁵ Upon
125 arrival, participants were allowed to rest for 5–10 min to adapt to the ambient conditions prior to
126 measurements.

127

128 ***2.3. Evaluation Procedures***

129 All protocol procedures were summarized in Table 2.

130

131 ***2.3.1. Symptomatology Assessment***

132 The DED symptomatology was quantified by a self-administered OSDI questionnaire by
133 scanning a QR code provided before the examination ²⁰; questions were asked concerning a 1-
134 week recall period following the standardized interview model.²¹ The scores obtained were
135 computed on a scale of 0 to 100 points by the researchers according to the published standardized
136 guidelines, where higher scores represent greater disability.²⁰

137

138 ***2.3.2. Tear Film Osmolarity***

139 The tear film osmolarity was measured by the TearLab osmometer (TearLab Corp, San Diego,
140 CA, United States).²² The participants were requested to sit with their heads tilted and their eyes
141 looking at the ceiling. Then, the instrument probe was placed on the lower tear meniscus of the
142 randomly selected eye until a beep was emitted, signalling that the sample was collected. The
143 TearLab converts the electrical impedance of the sample into osmolarity (mOsm/L), which was
144 displayed on the device screen. The contralateral eye was measured after a 5–10 min interval to
145 avoid inter-eye interference following the same protocol.⁵ In all cases, the same test card lot
146 number was used in both eyes. Quality control electronic check card was used regularly to verify
147 the correct stats of the system (if the reading was 334 ± 3 mOsm/L, the pen was working correctly).

148

149 ***2.3.3. Fluorescein Break-Up Time***

150 The FBUT was assessed by the Keratograph 5M (Oculus Optikgerate GmbH, Wetzlar, Germany)
151 using the fluorescein function.²³ The participants were instructed to properly place at the device
152 chin rest and to look up, then, in all cases, a fluorescein strip hydrated with saline solution was
153 applied to the patient's eye in the bulbar conjunctiva area in order to maintain a method to avoid
154 interference in the inter-patient evaluation results.²⁴ Once the dye was applied, the participants
155 were instructed to blink normally to ensure the adequate distribution of the fluorescein; then,
156 participants were requested to blink three times keeping the eyes open the long as possible until
157 the end of the test.²⁵ The time interval between the last blink and the appearance of the first black
158 spot on the corneal surface was defined as the FBUT. This entire procedure was videorecorded
159 and repeated three times for each participant.²⁵ These recorded videos were extracted, and the
160 FBUT was calculated by a second masked examiner with the open-source software VistualDub64
161 which converts the video into frames (8 frames = 1s), improving the temporal resolution. The
162 final values were computed based on the mean of the three measurements performed.²⁵

163

164 ***2.3.4. Corneal Staining***

165 The corneal staining was assessed by the Keratograph 5M (Oculus Optikgerate GmbH, Wetzlar,
166 Germany) using the fluorescein function immediately after the FBUT measurement.²³ To observe

167 the possible damage in the entire cornea, the participants were requested to look at a red target in
168 the centre of the device, subsequently, the participants were requested to look to the right, left, up
169 and down to assess the paracentral areas; the upper lid was slightly manipulated to evaluate the
170 upper part of the cornea during the look down.^{26,27} A second masked examiner evaluated the
171 extracted videos from this test using the Oxford Scheme, a six-scheme grade that denotes the
172 ocular surface damage severity: mild (stage 0 or 1), moderate (stage 2 or 3) or severe (stage 4 or
173 5).^{26,27}

174

175 **2.4. Statistical analysis**

176 SPSS statistical software v.25.0 for Windows (SPSS Inc., Chicago, IL, United States) was used
177 for data analysis. Significance was set at a $p \leq 0.05$ for all statistical tests. The inter-eye differences
178 parameters employed for the analysis were calculated as the absolute difference between values
179 obtained from both participant's eyes ($|OD-OS|$), being named as Osmolarity $|OD-OS|$, FBUT $|OD-$
180 $OS|$ and Corneal Staining $|OD-OS|$.^{9,28} Before analysis, the normal distribution of the data was
181 checked using the Kolmogorov-Smirnov test²⁹; all parameters showed a non-normal distribution
182 (Kolmogorov-Smirnov, all $p \leq 0.001$). The median, Interquartile Range (IQR), minimum and
183 maximum values were displayed as descriptive statistics, while parametric statistics (mean and
184 SD) are also reported to enable comparisons with other studies and clinical results. Differences
185 in the values obtained in each parameter between groups were analysed with the Mann-Whitney
186 U test for non-parametric variables.²⁹

187 The optimal threshold for discriminating between Non DED and DED in diagnostic terms was
188 determined through Receiver Operating Characteristics (ROCs) procedures.^{12,30} For each
189 hypothetical threshold value (ranging from the lowest to the highest value observed in the study
190 population), sensitivity and specificity of the test were calculated. Subsequently, these results
191 were graphed with sensitivity plotted against (1-specificity). The predictive classification model's
192 discriminatory capability was quantified as the Area Under the Curve (AUC), ranging from 0 (no
193 predictive power) to 1 (almost perfect predictive power), along with its SD. Moreover, upper and
194 lower 95% Confidence Intervals (CI) of the AUC were provided ($\text{mean} \pm 1.96 \times \text{SD}$).^{12,29}

195 Additionally, Youden's J statistic ($J = \text{sensitivity} + \text{specificity} - 1$) was calculated to ascertain the
196 optimal numerical criterion for each ROC curve.^{12,29}

197 In a subsequent reevaluation, a cross-validation procedure specifically targeting parameters
198 exhibiting diagnostic potential ($\text{AUC}, p \leq 0.05$) to assess the validity of the obtained cut-off
199 values was conducted on an 80% random sampling. The variables were then transformed into a
200 new dichotomous parameter, utilizing the calculated cut-off values (0 representing a negative
201 diagnosis, and 1 indicating a positive diagnosis). The association between the new parameter and
202 the initial diagnosis (TFOS DEWS II Diagnostic Methodology report) was examined using
203 Cramer's V, which ranges from 0 (no predictive ability) to 1 (perfect predictive ability).¹²

204

205 **3. RESULTS**

206 The Non-DED group showed an age median (IQR) = 40.0 (32.0-52.0) years and an OSDI score
207 median (IQR) = 10.42 (6.25-11.96); meanwhile, the DED group showed an age median (IQR) =
208 53.0 (41.0-61.0) years and an OSDI score median (IQR) = 29.55 (20.83-41.37). Descriptive
209 statistics for all the measurements performed in the study on each subgroup were provided in
210 Table 3. There was found a statistical difference in the Age, OSDI and Osmolarity|OD-OS|
211 between groups (Mann-Whitney U, all $p \leq 0.020$), whereas no statistical difference was found in
212 the FBUT|OD-OS| or Corneal Staining|OD-OS| values (Mann-Whitney U, both $p \geq 0.160$).

213

214 ***3.1. Assessment of Osmolarity|OD-OS| Cut-Off Values to Differentiate between No DED and*** 215 ***DED Participants***

216 ROCs procedures showed that Osmolarity|OD-OS| has a significant diagnostic capability to
217 differentiate between participants' diagnostic ($\text{AUC} = 0.745 \pm 0.052, p = 0.003, 95\% \text{ CI} = 0.643-$
218 0.847 , Figure 1). By calculating the Youden's index (Youden's J statistic = 0.491), there was
219 found a cut-off value for the Osmolarity|OD-OS| of 9.5 mOsm/L (specificity: 100.0%; sensitivity:
220 49.1%) to differentiate No DED from DED participants (Figure 1). The cross-validation analysis
221 on a random sampling of 80% showed an association of the calculated Osmolarity|OD-OS| cut-

222 off value with the previous proposed diagnostic criteria of the TFOS DEWS II to differentiate
223 between No DED and DED participants (Cramer's $V = 0.258$, $p = 0.003$).

224

225 ***3.2. Assessment of FBUT |OD-OS | cut-Off Values to Differentiate between No DED and DED***

226 ***Participants***

227 ROCs procedures showed that FBUT|OD-OS| has no significant diagnostic capability to
228 differentiate between participants' diagnostic (AUC = 0.617 ± 0.088 , $p = 0.160$, 95% CI = 0.586–
229 0.648, Figure 2).

230

231 ***3.3. Assessment of Corneal Staining |OD-OS| Cut-Off Values to Differentiate between No DED***

232 ***and DED Participants***

233 ROCs procedures showed that Corneal Staining|OD-OS| has no significant diagnostic capability
234 to differentiate between participants' diagnostic (AUC = 0.508 ± 0.076 , $p = 0.952$, 95% CI =
235 0.359–0.657, Figure 3).

236

237 **4. DISCUSSION**

238 In the present study, the absolute inter-eye difference value diagnostic capability of the three main
239 diagnostic criteria tests proposed by the TFOS DEWS II Diagnostic Methodology report was
240 analysed.¹ An inter-eye variability of the results during DED assessment has been proposed as a
241 characteristic that increases with disease severity, which has been recommended as a feature that
242 clinicians should specifically be looking at diagnosis.^{1,9,10} To the author's knowledge, from those
243 parameters, the only previously studied was the inter-eye osmolarity difference; however, most
244 of those studies have calculated this difference as a tangential analysis to the main objective of
245 their research.^{5,6,9,31-34}

246 The sample analysis in the present study was composed of participants with previous dry eye
247 complaints who attended an ocular surface examination at the centre referred by their medical
248 doctor or the health service of the institution. Although the FBUT|OD-OS| and the Corneal
249 Staining|OD-OS| showed no difference between groups and no reliable diagnostic cut-off criteria,

250 there should be noted that inter-eye differences median and IQR values in the three parameters
251 studied were clinically higher in the DED group than in the No DED group. However, it also
252 should be noted that despite the general trend of the data, there were sparse participants in the No
253 DED group (low symptomatology and no sign over the cut-off criteria in any eye) that still showed
254 high inter-eye differences (e.g. No DED group FBUT|OD-OS| maximum value = 8.75s), or even
255 the opposite situation in the DED group (e.g. No DED group Osmolarity|OD-OS| minimum value
256 = 0.00 mOsm/L). The DED condition was associated with various manifestations, such as non-
257 obvious disease involving ocular surface signs without related symptoms (including the
258 neurotrophic conditions where with the presence of dysfunctional sensation exists) and those with
259 symptoms but without demonstrable signs on the ocular surface (including neuropathic pain).^{1,2,8}
260 This issue has been established as a limitation in all the studies which pursue obtaining reliable
261 diagnostic tests, therefore, strict inclusion criteria and interprofessional collaboration are essential
262 for a proper diagnosis and management of the patients. Similar to other conditions, could be
263 proposed that the DED patient's quality of life may be benefited from regular multidisciplinary
264 management of different practice areas (e.g., neurologist, endocrinologist, or vision specialists).³⁵
265 In addition, this issue also remarks on the importance of searching for new diagnostic and reliable
266 criteria during the routine diagnosis of ocular surface diseases that avoid false negative or positive
267 diagnostics.

268 From the studied parameters, the present analysis found that only the Osmolarity|OD-OS| showed
269 a diagnostic capability to diagnose the DED in the same direction that the criteria proposed by the
270 TFOS Diagnostic methodology subcommittee report.¹ Previous reports have suggested that inter-
271 eye differences beyond the threshold of 8 or 9.2 ± 9.3 mOsm/l should be considered an indication
272 of the tear film homeostasis loss that occurs with DED.^{8,28} The absolute inter-eye osmolarity
273 difference found as a cut-off criterion in the present study was near this value (Osmolarity|OD-
274 OS| = 9.5 mOsm/L). Along with the stability, since the initial reports and definitions of the
275 disease,³⁶ tear film hyperosmolarity has been considered the main trigger and core mechanism in
276 dry eye physiopathology.³ Here was confirmed that, far from a single measurement where a higher
277 osmolarity in the tear film is recorded, the inter-eye variability of the tear osmolarity may be also

278 greater in DED than in healthy patients; therefore, this characteristic seems to increase with
279 disease severity and could be recommended as a feature that clinicians should specifically be
280 looking upon diagnosis.^{1,9}

281 Contrary to this finding, although “film instability” and “ocular surface inflammation and
282 damage” were included as key etiological factors in the definition of the disease, FBUT|OD-OS|
283 and the Corneal Staining|OD-OS| have not shown a diagnostic capability for DED diagnosis.²

284 Those parameters seem to evolve and worsen in the same proportion in both eyes at the same
285 time, without being affected by the homeostasis loss in the contralateral eye. Previous reports
286 found differences in the values of both, FBUT and Corneal Staining evaluated with the Oxford
287 Scheme, between open-angle glaucoma-diagnosed eyes treated medically and the fellow eyes
288 treated surgically of trabeculectomy; during the medication process, worse results are reported.³⁷

289 It could be hypothesised that conditions (pathologies or medications) that alter the homeostasis
290 of one eye have no influence on the damage or stability of the other. This issue may be
291 controversial and requires further analysis and research.

292 The main strength of the present study was the high total sample size recruited (180 participants).

293 In addition, it should be noted that participants were diagnosed under restrictive and accurate
294 diagnostic criteria according to the TFOS DEWS II Diagnostic Methodology.¹ On the other hand,
295 this criterion is established in the TFOS report (positive symptomatology combined with a
296 positive result on at least one clinical test in diagnosing dry eye) it might have limited the results;
297 some participants have been positively diagnosed as DED based on only a cut of criteria (e.g. an
298 osmolarity in either of eye ≥ 308 mOsm/l) which implies that the other studied inclusion criteria
299 are "normal" (e.g., which could implied no differences between eyes (e.g., FBUT in both patient's
300 eyes ≥ 10 s) and the subsequent no significant diagnostic capability on this parameter.

301 In summary, the present study found that Osmolarity|OD-OS| may be used as a diagnostic
302 indicator for DED, whereas FBUT|OD-OS| and Corneal Staining|OD-OS| seem to do not have
303 this capability; inter-eye differences in tear hyperosmolarity should be also considered a clinically
304 useful estimate for tear homeostasis. The present study proposed a cut-off value of

305 Osmolarity|OD-OS| to differentiate between the No DED and DED participants that should be
306 validated in further research in a different cohort of No DED versus DED participants.

307

308 **ACKNOWLEDGMENTS**

309 The authors report there are no acknowledgments to declare.

310

311 **DECLARATION OF INTEREST STATEMENT**

312 The authors report there are no competing interests to declare.

313

314 **REFERENCES**

- 315 1 Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK,
316 Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC,
317 Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. *The ocular surface*
318 2017; 15: 539-574.
- 319 2 Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols
320 JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. *The*
321 *ocular surface* 2017; 15: 276-283.
- 322 3 Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli
323 M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II
324 pathophysiology report. *The ocular surface* 2017; 15: 438-510.
- 325 4 Cai Y, Wei J, Zhou J, Zou W. Prevalence and Incidence of Dry Eye Disease in Asia: A
326 Systematic Review and Meta-Analysis. *Ophthalmic research* 2022; 65: 647-658.
- 327 5 Keech A, Senchyna M, Jones L. Impact of time between collection and collection method
328 on human tear fluid osmolarity. *Current eye research* 2013; 38: 428-436.
- 329 6 Nolfi J, Caffery B. Randomized comparison of in vivo performance of two point-of-care
330 tear film osmometers. *Clin Ophthalmol* 2017; 11: 945-950.

- 331 7 Gokhale M, Stahl U, Jalbert I. In situ osmometry: validation and effect of sample
332 collection technique. *Optometry and vision science : official publication of the American*
333 *Academy of Optometry* 2013; 90: 359-365.
- 334 8 Sullivan B. Challenges in using signs and symptoms to evaluate new biomarkers of dry
335 eye disease. *The ocular surface* 2014; 12: 2-9.
- 336 9 Lemp MA, Bron AJ, Baudouin C, Benitez Del Castillo JM, Geffen D, Tauber J, Foulks
337 GN, Pepose JS, Sullivan BD. Tear osmolarity in the diagnosis and management of dry
338 eye disease. *American journal of ophthalmology* 2011; 151: 792-798 e791.
- 339 10 Jacobi C, Jacobi A, Kruse FE, Cursiefen C. Tear film osmolarity measurements in dry
340 eye disease using electrical impedance technology. *Cornea* 2011; 30: 1289-1292.
- 341 11 Garcia-Queiruga J, Pena-Verdeal H, Sabucedo-Villamarin B, Garcia-Resua C, Giraldez
342 MJ, Yebra-Pimentel E. Analysis of the Differences in Ocular Surface Damage and
343 Inflammatory Signs between Healthy and Evaporative Dry Eye Participants. *Ocular*
344 *immunology and inflammation* 2022: 1-8.
- 345 12 Sabucedo-Villamarin B, Pena-Verdeal H, Garcia-Queiruga J, Giraldez MJ, Garcia-Resua
346 C, Yebra-Pimentel E. Categorization of the Aqueous Deficient Dry Eye by a Cut-Off
347 Criterion of TMH Measured with Tearscope. *Life (Basel)* 2022; 12.
- 348 13 Stanislaw PA, Stawicki MD. RESEARCH GUIDE: Guide to free statistical software:
349 general applications. *OPUS 12 Scientist* 2010; 4: 12-13.
- 350 14 Miller KL, Walt JG, Mink DR, Satram-Hoang S, Wilson SE, Perry HD, Asbell PA,
351 Pflugfelder SC. Minimal clinically important difference for the ocular surface disease
352 index. *Archives of ophthalmology* 2010; 128: 94-101.
- 353 15 Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with
354 dry eye disease: an online survey. *Current medical research and opinion* 2011; 27: 1041-
355 1048.
- 356 16 Pult H, Riede-Pult B. Comparison of subjective grading and objective assessment in
357 meibography. *Contact lens & anterior eye : the journal of the British Contact Lens*
358 *Association* 2013; 36: 22-27.

- 359 17 Arita R, Minoura I, Morishige N, Shirakawa R, Fukuoka S, Asai K, Goto T, Imanaka T,
360 Nakamura M. Development of Definitive and Reliable Grading Scales for Meibomian
361 Gland Dysfunction. *American journal of ophthalmology* 2016; 169: 125-137.
- 362 18 Garcia-Resua C, Pena-Verdeal H, Minones M, Giraldez MJ, Yebra-Pimentel E.
363 Interobserver and intraobserver repeatability of lipid layer pattern evaluation by two
364 experienced observers. *Contact lens & anterior eye : the journal of the British Contact
365 Lens Association* 2014; 37: 431-437.
- 366 19 Pena-Verdeal H, Garcia-Resua C, Barreira N, Giraldez MJ, Yebra-Pimentel E.
367 Interobserver variability of an open-source software for tear meniscus height
368 measurement. *Contact lens & anterior eye : the journal of the British Contact Lens
369 Association* 2016; 39: 249-256.
- 370 20 Akowuah PK, Adjei-Anang J, Nkansah EK, Fummey J, Osei-Poku K, Boadi P, Frimpong
371 AA. Comparison of the performance of the dry eye questionnaire (DEQ-5) to the ocular
372 surface disease index in a non-clinical population. *Contact lens & anterior eye : the
373 journal of the British Contact Lens Association* 2022; 45: 101441.
- 374 21 Fowler FJ. Improving Survey Questions: Design and Evaluation: SAGE Publications,
375 Inc, 1995.
- 376 22 Tavakoli A, Markoulli M, Flanagan J, Papas E. The validity of point of care tear film
377 osmometers in the diagnosis of dry eye. *Ophthalmic Physiol Opt* 2022; 42: 140-148.
- 378 23 Liu Q, Cheng W, Liu C, Jin X, Ming S, Zhao D, Feng X. Evaluation of effects of 3%
379 diquafosol ophthalmic solution on preocular tear film stability after trabeculectomy.
380 *International ophthalmology* 2022.
- 381 24 Johnson ME, Murphy PJ. The Effect of instilled fluorescein solution volume on the values
382 and repeatability of TBUT measurements. *Cornea* 2005; 24: 811-817.
- 383 25 Pena-Verdeal H, Garcia-Resua C, Ramos L, Yebra-Pimentel E, Giraldez MJ. Diurnal
384 variations in tear film break-up time determined in healthy subjects by software-assisted
385 interpretation of tear film video recordings. *Clinical & experimental optometry* 2016; 99:
386 142-148.

- 387 26 Kourukmas R, Roth M, Geerling G. Automated vs. human evaluation of corneal staining.
388 *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes*
389 *Archiv fur klinische und experimentelle Ophthalmologie* 2022; 260: 2605-2612.
- 390 27 Pena-Verdeal H, Noya-Padin V, Losada-Oubina M, Saborido-Rey M, Vilas-Alonso M,
391 Giraldez MJ. Changes of symptomatology, tear film and ocular surface integrity one
392 week during Somofilcon-A and Omafilcon-A lens wear. *European journal of*
393 *ophthalmology* 2022: 11206721221131131.
- 394 28 Pena-Verdeal H, Garcia-Resua C, Vazquez-Sanchez C, Garcia-Queiruga J, Giraldez MJ,
395 Yebra-Pimentel E. Inter-eye osmolarity differences in patients with symptomatic and
396 non-symptomatic dry eyes. *Arquivos brasileiros de oftalmologia* 2020; 83: 103-108.
- 397 29 Armstrong RA, Davies LN, Dunne MC, Gilmartin B. Statistical guidelines for clinical
398 studies of human vision. *Ophthalmic Physiol Opt* 2011; 31: 123-136.
- 399 30 Nahm FS. Receiver operating characteristic curve: overview and practical use for
400 clinicians. *Korean journal of anesthesiology* 2022; 75: 25-36.
- 401 31 Caffery B, Chalmers RL, Marsden H, Nixon G, Watanabe R, Harrison W, Mitchell GL.
402 Correlation of tear osmolarity and dry eye symptoms in convention attendees. *Optometry*
403 *and vision science : official publication of the American Academy of Optometry* 2014;
404 91: 142-149.
- 405 32 Ozsutcu M, Arslan B, Erdur SK, Gulkilik G, Kocabora SM, Muftuoglu O. Tear
406 osmolarity and tear film parameters in patients with unilateral pterygium. *Cornea* 2014;
407 33: 1174-1178.
- 408 33 Aslan Bayhan S, Bayhan HA, Muhafiz E, Bekdemir S, Gurdal C. Effects of
409 osmoprotective eye drops on tear osmolarity in contact lens wearers. *Can J Ophthalmol*
410 2015; 50: 283-289.
- 411 34 Szczesna-Iskander DH. Measurement variability of the TearLab Osmolarity System.
412 *Contact lens & anterior eye : the journal of the British Contact Lens Association* 2016;
413 39: 353-358.

414 35 Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, Schioldt
415 M, Umehara H, Vivino F, Zhao Y, Dong Y, Greenspan D, Heidenreich AM, Helin P,
416 Kirkham B, Kitagawa K, Larkin G, Li M, Lietman T, Lindegaard J, McNamara N, Sack
417 K, Shirlaw P, Sugai S, Vollenweider C, Witcher J, Wu A, Zhang S, Zhang W, Greenspan
418 J, Daniels T, Sjogren's International Collaborative Clinical Alliance Research G.
419 American College of Rheumatology classification criteria for Sjogren's syndrome: a data-
420 driven, expert consensus approach in the Sjogren's International Collaborative Clinical
421 Alliance cohort. *Arthritis Care Res (Hoboken)* 2012; 64: 475-487.

422 36 Farris RL, Gilbard JP, Stuchell RN, Mandel ID. Diagnostic tests in keratoconjunctivitis
423 sicca. *The CLAO journal : official publication of the Contact Lens Association of*
424 *Ophthalmologists, Inc* 1983; 9: 23-28.

425 37 Romano D, De Ruvo V, Fogagnolo P, Farci R, Rossetti LM. Inter-Eye Comparison of
426 the Ocular Surface of Glaucoma Patients Receiving Surgical and Medical Treatments. *J*
427 *Clin Med* 2022; 11.

428
429
430
431
432
433
434
435
436
437
438
439
440
441

442 **TABLES**

443 Table 1. Summary of the battery of clinical procedures performed ¹.

Classification	Symptoms	Signs
No DED	OSDI score < 13	All conditions must be filled: - Osmolarity in both eyes < 308 mOsm/l - FBUT in both eyes ≥ 10 s - Corneal staining (Oxford Scheme) in both eyes < 2
DED	OSDI score ≥ 13	Only one condition must be filled: - Osmolarity in either of the eyes ≥ 308 mOsm/l - FBUT in either of the eyes < 10 s - Corneal staining (Oxford Scheme) in either of the eyes ≥ 2

444 OSDI = Ocular Surface Disease Index; FBUT = Fluorescein Break-Up Time

445 Table 2. Summary of the battery of clinical procedures performed.

Parameter	Material	Method
Symptomatology Assessment	OSDI questionnaire.	Participants access the online survey by QR code. The questionnaire was self-administered.
Osmolarity	TearLab (TearLab, San Diego, CA, United States).	A probe was placed on the lower tear meniscus.
Fluorescein Break-Up Time	Oculus Keratograph 5M (Oculus Optikgerate GmbH, Wetzlar, Germany).	Instillation of fluorescein (fluorescein strip hydrated with saline solution) onto inferotemporal bulbar conjunctiva. A video was recorded and extracted for analysis by counting frames with the VirtualDub software by a second masked examiner.
Corneal Staining	Oculus Keratograph 5M (Oculus Optikgerate GmbH, Wetzlar, Germany).	Performed immediately after FBUT video recording. A video was recorded for analysis of the different corneal areas and evaluated by a second masked examiner.

446 OSDI = Ocular Surface Disease Index; FBUT = Fluorescein Break-Up Time

447 Corneal Staining|OD-OS| values.


Table 3. Descriptive statistics and analysis of differences (Mann-Whitney U test, non-parametric parameters) of the No DED and DED groups. Median and IQR are ported (non-parametric parameter), while parametric statistics (mean and SD) are also reported to enable comparisons with other studies and clinical results.

		Osmolarity (mOsm/L)			FBUT (seconds)			Corneal Staining (Oxford Scheme)		
		Eye Value	OD-OS		Eye Value	OD-OS		Eye Value	OD-OS	
		Mean ± SD	Mean ± SD	Median (IQR)	Mean ± SD	Mean ± SD	Median (IQR)	Mean ± SD	Mean ± SD	Median (IQR)
No DED	OD	303.0 ± 6.0	4.5 ± 3.3	4.0 (2.0-8.0)	15.35 ± 4.08	2.96 ± 2.21	2.17 (1.32-3.69)	0.3 ± 0.5	0.5 ± 0.5	0.0 (0.0-1.0)
	OS	301.9 ± 4.4			14.89 ± 2.46			0.6 ± 0.5		
DED	OD	323.1 ± 20.5	12.5 ± 12.2	9.0 (4.0-15.0)	7.19 ± 5.80	3.14 ± 3.76	3.38 (0.92-5.93)	0.8 ± 1.0	0.6 ± 0.7	0.0 (0.0-1.0)
	OS	325.8 ± 19.7			7.61 ± 6.85			0.8 ± 1.0		
p		-	-	0.002	-	-	0.160	-	-	0.915

DED = Dry Eye Disease. OD = Oculus Dexter. OS = Oculus Sinister. SD = Standard Deviation. IQR = Interquartile Range. OSDI = Ocular Surface Disease Index. FBUT = Fluorescein Break-Up Time. |OD-OS| = Inter-eye absolute difference

1 **FIGURES**


2 Figure 1.



3

4


5 Figure 2.



6

7

8 Figure 3.



10 **FIGURE CAPTIONS**

11 Figure 1. ROC curve showing the relationship between sensitivity and specificity of the
12 Osmolarity|OD-OS| (No DED vs. DED) according to theoretical thresholds; for each of the values
13 observed in the study population (from the lowest to the highest in either No DED or the DED
14 group), the sensitivity and sensibility indexes have been calculated and reported in the graph. n =
15 180. ROC = Receiver Operating Characteristic. DED = Dry Eye Disease. |OD-OS| = Inter-eye
16 absolute difference.

17 Figure 2. ROC curve showing the relationship between sensitivity and specificity of the
18 FBUT|OD-OS| (No DED vs. DED) according to theoretical thresholds; for each of the values
19 observed in the study population (from the lowest to the highest in either No DED or the DED
20 group), the sensitivity and sensibility indexes have been calculated and reported in the graph. n =
21 180. ROC = Receiver Operating Characteristic. DED = Dry Eye Disease. |OD-OS| = Inter-eye
22 absolute difference.

23 Figure 3. ROC curve showing the relationship between sensitivity and specificity of the Corneal
24 Staining |OD-OS| (No DED vs. DED) according to theoretical thresholds; for each of the values
25 observed in the study population (from the lowest to the highest in either No DED or the DED
26 group), the sensitivity and sensibility indexes have been calculated and reported in the graph. n =
27 180. ROC = Receiver Operating Characteristic. DED = Dry Eye Disease. |OD-OS| = Inter-eye
28 absolute difference.